Match!
Daniel J. Coleman
Oregon Health & Science University
EnzalutamideProstate cancerCancer researchAndrogen receptorMedicine
14Publications
4H-index
64Citations
What is this?
Publications 14
Newest
#1Theodore P. Braun (OHSU: Oregon Health & Science University)H-Index: 11
#2Cody Coblentz (OHSU: Oregon Health & Science University)H-Index: 3
Last. Julia E. Maxson (OHSU: Oregon Health & Science University)H-Index: 13
view all 10 authors...
Acute myeloid leukemia (AML) is a deadly hematologic malignancy with poor prognosis, particularly in the elderly. Even among individuals with favorable-risk disease, approximately half will relapse with conventional therapy. In this clinical circumstance, the determinants of relapse are unclear, and there are no therapeutic interventions that can prevent recurrent disease. Mutations in the transcription factor CEBPA are associated with favorable risk in AML. However, mutations in the growth fact...
Source
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 4
#2David A. Sampson (OHSU: Oregon Health & Science University)H-Index: 2
Last. Ilsa Coleman (Fred Hutchinson Cancer Research Center)H-Index: 41
view all 17 authors...
Abstract Neuroendocrine prostate cancer (NEPC) is the most virulent form of prostate cancer. Importantly, our recent work examining metastatic biopsy samples demonstrates NEPC is increasing in frequency. In contrast to prostate adenocarcinomas that express a luminal gene expression program, NEPC tumors express a neuronal gene expression program. Despite this distinction, the diagnosis of NEPC is often challenging, demonstrating an urgent need to identify new biomarkers and therapeutic targets. O...
1 CitationsSource
#1Claire B Turina (OHSU: Oregon Health & Science University)H-Index: 1
Last. Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 26
view all 5 authors...
: Nearly all prostate cancers start out as adenocarcinomas driven by the androgen receptor (AR). Neuroendocrine prostate cancer (NEPC) is a rare, AR-independent subtype with a poor prognosis and limited treatment options. Importantly, because of the widespread use of novel AR-targeting agents, the incidence of treatment-emergent (t)-NEPC is increasing in frequency. Molecular features commonly found in prostate adenocarcinomas are now well-recognized, including defects in homologous recombination...
Source
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 4
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 7
Last. Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 26
view all 15 authors...
BET bromodomain inhibitors block prostate cancer cell growth at least in part through c-Myc and androgen receptor (AR) suppression. However, little is known about other transcriptional regulators whose suppression contributes to BET bromodomain inhibitor anti-tumor activity. Moreover, the anti-tumor activity of BET bromodomain inhibition in AR-independent castration-resistant prostate cancers (CRPC), whose frequency is increasing, is also unknown. Herein, we demonstrate that BET bromodomain inhi...
5 CitationsSource
#1Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 4
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 7
Last. Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 26
view all 13 authors...
The BET bromodomain protein BRD4 is a chromatin reader that regulates transcription, including in cancer. In prostate cancer, specifically, the anti-tumor activity of BET bromodomain inhibition has been principally linked to suppression of androgen receptor (AR) function. MYC is a well-described BRD4 target gene in multiple cancer types, and prior work demonstrates that MYC plays an important role in promoting prostate cancer cell survival. Importantly, several BET bromodomain clinical trials ar...
7 CitationsSource
#1Archana SehrawatH-Index: 6
#2Dae Hwan KimH-Index: 2
Last. Joshi J. AlumkalH-Index: 26
view all 25 authors...
Source
#1Archana Sehrawat (OHSU: Oregon Health & Science University)H-Index: 6
#2Lina Gao (OHSU: Oregon Health & Science University)H-Index: 7
Last. Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 26
view all 24 authors...
Medical castration that interferes with androgen receptor (AR) function is the principal treatment for advanced prostate cancer. However, clinical progression is universal, and tumors with AR-independent resistance mechanisms appear to be increasing in frequency. Consequently, there is an urgent need to develop new treatments targeting molecular pathways enriched in lethal prostate cancer. Lysine-specific demethylase 1 (LSD1) is a histone demethylase and an important regulator of gene expression...
42 CitationsSource
#1Carly J. King (OHSU: Oregon Health & Science University)H-Index: 5
#2Josha Woodward (OHSU: Oregon Health & Science University)H-Index: 3
Last. Joshi J. AlumkalH-Index: 26
view all 12 authors...
// Carly J. King 1 , Josha Woodward 2 , Jacob Schwartzman 2 , Daniel J. Coleman 2 , Robert Lisac 2 , Nicholas J. Wang 1 , Kathryn Van Hook 2 , Lina Gao 2 , Joshua Urrutia 2 , Mark A. Dane 1 , Laura M. Heiser 1, * and Joshi J. Alumkal 2, * 1 Department of Biomedical Engineering, OHSU Center for Spatial Systems Biomedicine, Oregon Health and Science University, Portland, OR 97239, USA 2 Knight Cancer Institute, Oregon Health and Science University, Portland, OR 97239, USA * These authors have cont...
1 CitationsSource
#1Archana SehrawatH-Index: 6
#2Lina GaoH-Index: 7
Last. Joshi J. AlumkalH-Index: 26
view all 19 authors...
Source
#1Lina Gao (OHSU: Oregon Health & Science University)H-Index: 7
#2Daniel J. Coleman (OHSU: Oregon Health & Science University)H-Index: 4
Last. Joshi J. Alumkal (OHSU: Oregon Health & Science University)H-Index: 26
view all 10 authors...
Background: While treatment options for patients with castration-resistant prostate cancer (CRPC) are expanding, one American man is still predicted to die every 19 minutes from this disease this year. Moreover, more widespread use of novel and more potent AR-targeting agents has led to increased clinical frequency of virulent androgen and AR-independent CRPC subsets(Small, Huang et al. 2015). Currently, there are limited treatment options for men with CRPC who are resistant to these AR-targetin...
1 CitationsSource
12